"We have been investing in novel technologies, particularly in the area of biotechnology and have also been exploring partnerships to bring critical care therapies to the marketplace. Microbix' Urokinase strengthens our critical care portfolio and enhances our ability to globalize our capabilities," the statement quoted Pankaj Patel, chairman and managing director of Zydus Cadila as saying.